Investorideas.com

Get great ideas from our AI, cannabis, cleantech, crypto, esports and mining podcasts - be a guest or sponsor : 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Investor Ideas Adds New Nasdaq Stocks in Biotech: RLAY, IVA, NKTX, PSTX
Point Roberts, WA and Delta, BC - July 31, 2020 (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor resource announces its weekly roundup of stocks added to its global stock directories, including biotech and mining.

Coverage Initiated on 'Emerging Colossus in Diagnostics and Life Science'
July 30, 2020 (Investorideas.com Newswire) Meridian Bioscience's business segments, revenue and growth as well as COVID-19's positive impact on them are reviewed in an H.C. Wainwright & Co. report.

Kodak Shares Triple in a Flash on $765 Million Loan from DFC for New Pharmaceutical Unit
July 29, 2020 (Investorideas.com Newswire) Eastman Kodak shares traded more than 200% higher after the company reported it is forming a new business unit to produce essential pharmaceutical components funded by the U.S. International Development Finance Corporation.

TCR2 Therapeutics Reports Positive Results in Mesothelin-Expressing Solid Tumor Study
July 28, 2020 (Investorideas.com Newswire) Shares of TCR2 Therapeutics traded 30% higher after the firm released encouraging results from the Phase 1 portion of its clinical study of TC-210 in treating advanced mesothelin-expressing solid tumors.

Coronavirus / Biotech Stock News Bites: Moderna (Nasdaq: $MRNA) Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins
CAMBRIDGE, Mass - July 27, 2020 (Investorideas.com Newswire) Coronavirus / Biotechnology (COVID-19) Stock News Bites - Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 has begun dosing participants.

Global Healthcare Interoperability Market to Witness Nearly Two-fold Growth by 2024
Santa Clara, Calif. - July 27, 2020 (Investorideas.com Newswire) Frost & Sullivan's recent analysis, Global Healthcare Interoperability Market, Forecast to 2024, contends that interoperability has become a critical consideration for all health IT (HIT) applications.

Short Updates on Benchmark, TriStar Gold, Precipitate Gold and Lion One
July 24, 2020 (Investorideas.com Newswire) With gold and silver "climbing to the moon," Bob Moriarty of 321gold discusses four juniors.

HCA Healthcare Shares Move Up on Q2 Earnings and Resumption of Non-Emergency Procedures
July 23, 2020 (Investorideas.com Newswire) Shares of HCA Healthcare traded more than 10% higher after the company reported Q2/20 financial results and advised it has seen a gradual rise in patient volumes in May and June for elective and non-emergency procedures.

Biopharma's Therapeutic Jumps to Phase 2 Testing for COVID-19 'to Shut Down the Cytokine Storm'
July 23, 2020 (Investorideas.com Newswire) A development update on Sorrento Therapeutics' three coronavirus-related products is provided in a Dawson James report.

Cheap Valuation and Fastest Revenue Growth in Telemedicine? Analyst Says Yes.
July 20, 2020 (Investorideas.com Newswire) In the time of Covid-19, Peter Epstein of Epstein Research breaks down the investment opportunity offered by CloudMD.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Sponsored Financial Content and Guest Posts

Buy a guest post on Investorideas.com

Everything You Need to Know About Investing in Healthcare Stocks

March 30, 2020 (Investorideas.com Newswire) Healthcare is one of the most favorable areas for stock investors, mainly because of the roughly $7 trillion that's invested in it across the world - in a single year.

The Rise Of The At-Home Testing Market

January 16, 2020 (Investorideas.com Newswire) Have you heard the term personalized medicine? It's the buzzword in use today thanks to the increase in medical tests being conducted at home.

Why Do You Need Birth Injury Lawyer and How They Can Help You?

October 2, 2019 (Investorideas.com Newswire) Childbirth injury is inexcusable. From the moment a child is conceived to the time the delivery is done, it is the responsibility of the doctors to see that the child is delivered with the utmost care and is healthy.

5 Key Tips For Renting a Boardroom

August 14, 2018 (Investorideas.com Newswire) You've arranged to rent virtual offices in Toronto from time to time.

How to Go About Choosing a Medical Malpractice Lawyer

February 13, 2018 (Investorideas.com Newswire) Medical malpractice affects thousands of individuals around the world. If you think you have been injured, or wrongfully treated by a medical professional, you may be entitled to compensation.

Biotech News from Newsfile

Media Central Corporation Inc. Completes Shares for Debt Transaction
Toronto, Ontario--(Newsfile Corp. - January 31, 2020) - Media Central Corporation Inc. (CSE: FLYY) (FSE: 3AT) ("MediaCentral" or the "Company") reports that its Board of Directors has approved the settlement of $271,200 in aggregate of debt through the issuance of common shares of the Company (the "Debt Settlement"). Pursuant to the Debt Settlement, MediaCentral would issue 3,190,588 common shares of the Company (the "Shares") at a deemed price of $0.085 per Share to certain creditors...

American Aires Announces Agreement with Answer 365 and to Partner with Four Fulfillment Centers
Toronto, Ontario--(Newsfile Corp. - January 31, 2020) - American Aires Inc. (CSE: WIFI) (the "Company" or "Aires") is pleased to announce that it has entered into a call centre service agreement (the "Service Agreement") effective January 28, 2020 with Answer 365, a Canadian call center, pursuant to which Answer 365 will outsource Aires' customer service providing 24-hour support and increased purchase satisfaction for Aires' customers around the world.. The Service Agreement may be terminated by...

EGF Theramed Announces Change of Directors and New CEO
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2020) - EGF Theramed Health Corp. (CSE: TMED) has appointed David Bentil and Jatinder Dhaliwal to the board of EGF Theramed Health Corp. Mr. Bentil will assume the role of CEO and Mr. Dhaliwal will assume the role of director. Mr. Bentil is an Economist by trade. In 2002, he decided to follow his passion by pursuing a career in the car business which has done for over...

Rainmaker Worldwide and Pi Eco Announce a Strategic Investment and Global Reseller Agreement
Peterborough, Ontario--(Newsfile Corp. - January 30, 2020) - Rainmaker Worldwide Inc. (OTC Pink: RAKR) is extremely pleased to announce a comprehensive strategic investment by Pi Eco USA (www.pi.eco). This investment brings working capital for Rainmaker to fuel growth and upcoming deployments.In addition to the 500,000 USD capital injection, Pi Eco provides distributor and executive synergies that will be invaluable to Rainmaker and Pi Eco. Pi Eco has well-developed strategic relationships in Asia, Middle East, Central...

Cell MedX Corp. Reacquires World Wide Exclusivity Rights for the eBalance(R) Device
Carson City, Nevada--(Newsfile Corp. - January 30, 2020) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has repurchased the worldwide exclusive direct rights for distribution of its eBalance® devices.Cell MedX identified two distribution market channels for sales of the eBalance® device, individual rights for home...

Subscribe to Biotech News